By Fineline Cube Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC‑1327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first‑in‑human studies of the company’s ophthalmology pipeline candidate.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China NMPA |
| Approval Type | Clinical trial approval |
| Product | ORIC‑1327 (selective small‑molecule inhibitor) |
| Indication | Glaucoma and ocular hypertension |
| Announcement Date | 13 Aug 2026 |
| Next Steps | Initiation of clinical trials in China |
Drug Profile & Mechanism of Action
- Molecule: ORIC‑1327, a selective small‑molecule inhibitor with full proprietary intellectual property rights
- Indication: Intended for the treatment of patients with glaucoma and ocular hypertension
- Mechanism: Designed to lower intraocular pressure (IOP), the principal modifiable risk factor in glaucoma
- Intellectual Property: Fully proprietary to Chongqing Pharscin Pharmaceutical, supporting independent development and commercialization rights
Preclinical Evidence
| Element | Detail |
|---|---|
| Animal Models | New Zealand rabbits and cynomolgus monkeys |
| Efficacy Readout | Significant intraocular pressure‑lowering effects |
| Safety | Favorable ocular safety profile |
| Conclusion | Promising drugability prospects supporting clinical advancement |
Preclinical studies in two relevant species demonstrated that ORIC‑1327 delivers statistically meaningful reductions in intraocular pressure while maintaining favorable ocular tolerability — a combination that supports its progression into clinical development.
Market Impact & Outlook
- Disease Burden: Glaucoma is one of the leading causes of irreversible blindness worldwide, and ocular hypertension is its most important modifiable risk factor, creating a large chronic‑therapy market.
- Mechanism Differentiation: A selective small‑molecule approach to IOP reduction could complement or compete with existing prostaglandin analogs, beta‑blockers, and Rho‑kinase inhibitors, particularly for patients with inadequate response or tolerability issues.
- Pipeline Momentum: The clinical trial approval validates Chongqing Pharscin’s ophthalmology platform and extends its innovative portfolio beyond established franchises.
- Strategic Positioning: With full proprietary IP, ORIC‑1327 gives Pharscin full control over development and potential partnership leverage in the fast‑growing glaucoma therapeutic market.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, trial outcomes, and commercial potential for ORIC‑1327. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics in the ophthalmology market.-Fineline Info & Tech